ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
9.25
+0.96 (11.58%)
At close: Mar 27, 2026, 4:00 PM EDT
9.40
+0.15 (1.62%)
After-hours: Mar 27, 2026, 7:59 PM EDT
ADMA Biologics Employees
As of December 31, 2025, ADMA Biologics had 647 total employees, including 640 full-time and 7 part-time employees. The number of employees decreased by 38 or -5.55% compared to the previous year.
Employees
647
Change (1Y)
-38
Growth (1Y)
-5.55%
Revenue / Employee
$788,521
Profits / Employee
$227,094
Market Cap
2.20B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 647 | -38 | -5.55% | 640 | 7 |
| Dec 31, 2024 | 685 | 61 | 9.78% | 677 | 8 |
| Dec 31, 2023 | 624 | 7 | 1.13% | 624 | 0 |
| Dec 31, 2022 | 617 | 90 | 17.08% | 617 | 0 |
| Dec 31, 2021 | 527 | 120 | 29.48% | 527 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Apellis Pharmaceuticals | 739 |
| Ascentage Pharma Group International | 605 |
| Beam Therapeutics | 511 |
| Syndax Pharmaceuticals | 298 |
| Day One Biopharmaceuticals | 178 |
| Immunome | 177 |
| Disc Medicine | 155 |
ADMA News
- 2 days ago - ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating - GlobeNewsWire
- 2 days ago - ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research - GlobeNewsWire
- 2 days ago - $ADMA Shareholders: ADMA Biologics Hit with Securities Fraud Investigation After Stock Slides 29% Amid Channel Stuffing Claims – Investors with Losses Alerted to Contact BFA Law - GlobeNewsWire
- 3 days ago - ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law - Business Wire
- 4 days ago - Short Seller Report Alleges ADMA Biologics Financial Misrepresentation - Benzinga
- 4 days ago - ADMA Biologics Addresses Misleading Short-Seller Report - GlobeNewsWire
- 27 days ago - ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative - GlobeNewsWire
- 4 weeks ago - ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript - Seeking Alpha